SEC Form 3 · accession 0001209191-18-005225
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ted Ebel
Director
Period of report
Jan 24, 2018
Accepted (ET)
Jan 24, 2018 · 6:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 12,355 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | $1.83 | holding | — | — | — | — | Feb 2, 2026 | Common Stock | 18,164 | — | D |
| Stock OptionF1,F2 | $4.83 | holding | — | — | — | — | Aug 24, 2027 | Common Stock | 3,662 | — | D |
| Stock OptionF1,F2 | $7.01 | holding | — | — | — | — | Nov 30, 2027 | Common Stock | 9,097 | — | D |
Explanation of responses
- F1Reflects a 1-for-2.6975 reverse stock split of the Issuer's capital stock effected on January 8, 2018.
- F2The shares subject to the option will vest over a period of four years, with 1/48th of the shares subject to the option vesting monthly.